The FDA asked for public comments regarding how pharmaceutical companies should be held accountable for a communication about its product(s) and how much control they exert over activities on the Internet, regardless of whether the promotional activity occurs on company-sponsored venues or on third-party venues. Related to this, FDA also asked whether or not pharmaceutical companies should correct misconceptions or misinformation about their products, including unapproved uses of their products that are being conveyed on a Web site outside their control, such as on a blog, social networking site, or a wiki Web site (i.e., Wikipedia).
A substantial portion of the comments submitted to the FDA by the drug industry in response to the FDA was devoted to the accountability issue and the related issue of correcting misinformation on social media sites.
Topic headings include:
- Who Controls the Content?
- Some Communications Are of No Concern to FDA
- Owned, Earned, Shared Media
- Alternative Schemas
- Conversation Is Not Advertising Says Lilly
- Content Syndication
- User-Generated Content
- Patient Advocacy Special Case
- Safe Harbor for Corrections to Misinformation